Adare Pharma Solutions: Company Research Report

Company Overview

• Name: Adare Pharma Solutions

• Mission: Transforming drug delivery and transforming lives through innovative drug delivery solutions.

• Founded: No information is available.

• Founders: No information is available.

• Key People:

• Tom Sellig - Chief Executive Officer

• Michael Ryan - Chief Financial Officer/Chief Operations Officer

• Kristin Berkinsky - Chief Human Resources Officer

• Russell Lindenfeldar - Chief Legal Officer

• Audrey Butler - Vice President, Global Operational Excellence

• Shawn Watson - Vice President, Global Quality

• Headquarters: 7722 Dungan Road, Philadelphia, PA 19111, USA

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Adare Pharma Solutions is known for its role as a global technology-driven CDMO (Contract Development and Manufacturing Organization), providing specialized services in drug delivery platforms focused on oral dosage forms. The company has developed and manufactured more than 65 products sold in over 100 countries.

Products

Overview of Products

Adare Pharma Solutions specializes in delivering complex and customizable oral drug delivery solutions, with key offerings including:

• Advatab®: Orally-disintegrating dosage solution, providing taste masking and rapid dissolution in the mouth without water.

• Diffutab®: Targeted drug delivery platform for high-dosage and sustained release products, designed for once-daily administration.

• Diffucaps®: Controls drug delivery and optimizes release profiles, enhancing bioavailability.

• Microcaps®: Taste-masking solution using precision-coated individual drug particles for pleasant mouthfeel and no aftertaste.

• Minitabs™: Combines tablet formulation simplicity with multiparticulate flexibility, allowing high drug-loading.

• Parvulet®: Patient-centric oral dosing solution, especially for pediatric and geriatric populations with swallowing difficulties.

• Stratµm™: Innovative micro-encapsulation technology for injectable drug delivery products.

• Optimμm®: High drug loading oral microcapsules for taste masking, enteric coatings, and extended-release applications.

• Unisun®: Intratympanic delivery for treating otic disorders.

• Adaptdose™: Technology platform to avoid reformulation after Phase I, optimizing drug release and therapeutic performance.

• Duragran™: Controlled release beadlets/granules for uniform particle size distribution.

Recent Developments

Key Recent Developments

1. Headquarters Relocation:

• Announced in September 2024, Adare Pharma Solutions relocated its global headquarters from New Jersey to Philadelphia, Pennsylvania. This move was supported by a $2.9 million investment from Pennsylvania’s economic development funds, set to create 115 new jobs and retain 200 others.

2. 3D Printing Collaboration with Laxxon:

• In September 2024, Adare announced a partnership with Laxxon Medical for implementing cGMP 3D printing capabilities at Adare's Pessano facility in Milan, Italy. This collaboration aims to utilize Laxxon’s SPID® Technology for creating customizable release profiles in oral dosage forms.

3. Expansion Projects:

• Significant infrastructure expansions have been made in Adare’s Philadelphia manufacturing and packaging facilities, contributing to the improved efficacy and flexibility of their operations in North America and Europe.

4. Board of Directors Appointment:

• As of October 18, 2024, Adare CEO Tom Sellig was appointed to the Greater Philadelphia Chamber of Commerce board, reflecting Adare’s growing influence and collaboration within the Philadelphia region.

4. Investment in Pennsylvania:

• In August 2024, the Commonwealth of Pennsylvania invested nearly $3 million in Adare. This financial support aligns with Adare's expansion strategy and relocation of headquarters, enhancing their operational capabilities in life sciences.

Note

This report has been compiled strictly with the available data provided. Where no information was found, the corresponding field was noted as "No information is available." This ensures the inclusion of only verifiable and specific details in line with the provided sources.